2-methylthiomethyltetrahydrofuran | 24885-62-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 氧唑烯
• 英文名称: 2-methylthiomethyltetrahydrofuran
• 英文别名: 2-[(Methylsulfanyl)methyl]tetrahydrofuran；2-(methylsulfanylmethyl)oxolane
• CAS: 24885-62-9
• 化学式: C₆H₁₂OS
• mdl: MFCD21339983
• 分子量: 132.227
• InChiKey: YZJJZAODCCEFNT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  8
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  34.5
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  苯基硫代-4-戊烯醇 在 silica gel 、 N,N-二异丙基乙胺 作用下， 以 乙醚 、 乙腈 为溶剂， 反应 1.0h， 生成 2-methylthiomethyltetrahydrofuran
  参考文献：
  名称：

  Tuladhar, Sudersan M.; Fallis, Alex G., Canadian Journal of Chemistry, 1987, vol. 65, p. 1833 - 1837

  摘要：

  DOI：

文献信息

• Inhibitors of c-Jun N-terminal kinases
  申请人：Liu Gang

  公开号：US20060173050A1

  公开（公告）日：2006-08-03

  The present invention relates to compounds that are inhibitors of c-jun N-terminal kinase 1, 2, or 3 (JNK1, JNK2, or JNK3), compositions containing the compounds and the use of the compounds in the prevention or treatment of disorders regulated by the activation of JNK1, JNK2 and JNK3.

  本发明涉及作为c-jun N-末端激酶1、2或3（JNK1、JNK2或JNK3）抑制剂的化合物，包含这些化合物的组合物以及这些化合物在预防或治疗由JNK1、JNK2和JNK3激活调控的疾病中的用途。
• Phenylsulfenyl chloride/N,N-diisopropylethylamine: A useful reagent for cyclic ether formation (sulfenyletherification)
  作者：Sudersan M Tuladhar、Alex G Fallis

  DOI：10.1016/s0040-4039(00)95772-1

  日期：1987.1

  A general method for the formation of cyclic ethers and lactones is described. The procedure employs phenylsulfenyl chloride and N,N-diisopropylethylamine to generate an episulfonium ion intermediate from which the cyclic products arise by internal nucleophilic displacement.

  描述了形成环醚和内酯的一般方法。该方法使用苯基亚磺酰氯和N，N-二异丙基乙胺生成表s离子中间体，通过内部亲核取代从中生成环状产物。
• Pyrimidine derivatives as ghrelin receptor modulators
  申请人：Kosogof Christi

  公开号：US20050070712A1

  公开（公告）日：2005-03-31

  The present invention is related to compounds of formula (I), or a therapeutically suitable salt or prodrug thereof, the preparation of the compounds, compositions containing the compounds and the use of the compounds in the prevention or treatment of disorders regulated by ghrelin including anorexia, cancer cachexia, eating disorders, age-related decline in body composition, weight gain, obesity, and diabetes mellitus.

  本发明涉及式(I)的化合物，或者其治疗上适宜的盐或前药，该化合物的制备、含有该化合物的组合物以及在预防或治疗由生长激素释放素调节的疾病中使用该化合物，包括厌食症、癌症恶病质、进食障碍、与年龄相关的身体组成下降、体重增加、肥胖和糖尿病。
• Diaminopyrimidine derivatives as growth hormone secrectgogue receptor (GHS-R) antagonists
  申请人：Kosogof Christi

  公开号：US20050171131A1

  公开（公告）日：2005-08-04

  The present invention is related to compounds of formula (I), or a therapeutically suitable salt or prodrug thereof, the preparation of the compounds, compositions containing the compounds and the use of the compounds in the prevention or treatment of disorders regulated by the action of ghrelin receptor, including Prader-Willi syndrome, eating disorder, weight gain, weight-loss maintainance following diet and exercise, obesity, and disorders associated with obesity such as noninsulin dependent diabetes mellitus.

  本发明涉及式(I)的化合物，或其治疗上适用的盐或前药，所述化合物的制备，含有所述化合物的组合物以及在预防或治疗由胃泌素受体调节的疾病中使用所述化合物，包括普拉德-威利综合征、进食障碍、体重增加、饮食和锻炼后体重减轻维持、肥胖，以及与肥胖相关的疾病，如非胰岛素依赖型糖尿病。
• [EN] IMIDAZOTRIAZINE DERIVATIVES AS CD73 INHIBITORS<br/>[FR] DÉRIVÉS D'IMIDAZOTRIAZINE EN TANT QU'INHIBITEURS DE CD73
  申请人：BIOARDIS LLC

  公开号：WO2020210970A1

  公开（公告）日：2020-10-22

  The present disclosure relates generally to imidazotriazine derivatives that are inhibitors of CD73 and are useful in treating CD73-associated diseases or conditions. Compositions containing the compounds of the present disclosure are also provided.

  本公开涉及一般为CD73抑制剂的咪唑三嗪衍生物，可用于治疗CD73相关的疾病或病情。本公开还提供了含有本公开化合物的组合物。